- Home
- Publications
- Publication Search
- Publication Details
Title
Is There a Role for Immunotherapy in Prostate Cancer?
Authors
Keywords
-
Journal
Cells
Volume 9, Issue 9, Pages 2051
Publisher
MDPI AG
Online
2020-09-08
DOI
10.3390/cells9092051
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer
- (2020) Sevda Jafari et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
- (2020) William R. Berry et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.
- (2020) Julie Nicole Graff et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Evan Y. Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
- (2020) Michael Paul Kolinsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes
- (2020) Mélanie Claps et al. CANCER TREATMENT REVIEWS
- Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
- (2020) Matthias Pinter et al. GUT
- A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
- (2020) Julie N Graff et al. Journal for ImmunoTherapy of Cancer
- Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
- (2020) Veronica Mollica et al. Cancers
- An update on the immune landscape in lung and head and neck cancers
- (2020) Jennifer W. Carlisle et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis
- (2020) Francesco Massari et al. Expert Opinion On Drug Safety
- Role of Immunotherapy in Advanced Gastroesophageal Cancer
- (2020) Gretel Terrero et al. Current Oncology Reports
- Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
- (2020) Byung Woog Kang et al. ESMO Open
- Tumor mutational burden (TMB) standardization initiatives: Recommendations for consistent TMB assessment in clinical samples to guide immunotherapy treatment decisions
- (2019) Albrecht Stenzinger et al. GENES CHROMOSOMES & CANCER
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer
- (2019) Veronica Mollica et al. Cells
- Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
- (2019) James L. Gulley et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
- (2019) Sumanta Pal et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Emerging therapeutic targets for patients with advanced prostate cancer
- (2019) Fred Saad et al. CANCER TREATMENT REVIEWS
- Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
- (2019) Pengfei Zhao et al. Journal of Hematology & Oncology
- Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization
- (2019) Melissa A. Reimers et al. Current Urology Reports
- Immunotherapy and urothelial carcinoma: An overview and future prospectives
- (2019) Francesco Pierantoni et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
- (2018) A R Hansen et al. ANNALS OF ONCOLOGY
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- (2018) Yi-Mi Wu et al. CELL
- Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.
- (2018) Minke Smits et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
- (2018) Joseph W. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
- (2018) Conor E. Steuer et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
- (2018) Karim Boudadi et al. Oncotarget
- PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
- (2018) Pedro Isaacsson Velho et al. Expert Review of Clinical Pharmacology
- Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming
- (2018) Laura E. Johnson et al. OncoImmunology
- Microsatellite instability in prostate cancer by PCR or next-generation sequencing
- (2018) Jennifer A. Hempelmann et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy in melanoma
- (2018) Tara C Mitchell et al. Immunotherapy
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
- (2018) Daniel Nava Rodrigues et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer.
- (2018) Maialen Barrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer
- (2018) Emmanuel S. Antonarakis NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks
- (2018) Michael C. Comiskey et al. Current Oncology Reports
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Current status of immunotherapy in metastatic colorectal cancer
- (2018) Pawel Wrobel et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Updates and novel treatments in urothelial carcinoma
- (2018) Kirollos S Hanna JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
- (2018) Fatima Karzai et al. Journal for ImmunoTherapy of Cancer
- Immune Checkpoint Inhibition in Metastatic Urothelial Cancer
- (2017) Tom Powles et al. EUROPEAN UROLOGY
- Immunotherapy for Prostate Cancer: Where We Are Headed
- (2017) Giuseppe Schepisi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
- (2017) Farhad Fakhrejahani et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
- (2017) Christopher R Heery et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
- (2017) Steven Lemery et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- AR-V7 and prostate cancer: The watershed for treatment selection?
- (2016) Chiara Ciccarese et al. CANCER TREATMENT REVIEWS
- Association of ARV7 expression with molecular and clinical characteristics in prostate cancer.
- (2016) Himanshu Joshi et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
- (2016) Michael T. Schweizer et al. Oncotarget
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
- (2015) H. Gevensleben et al. CLINICAL CANCER RESEARCH
- Trends in Management for Patients With Localized Prostate Cancer, 1990-2013
- (2015) Matthew R. Cooperberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
- (2015) A M Martin et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
- (2015) Michal Podrazil et al. Oncotarget
- Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial
- (2015) Naomi B Haas et al. Journal for ImmunoTherapy of Cancer
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
- (2014) Lawrence Fong et al. JNCI-Journal of the National Cancer Institute
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
- (2014) Colin C. Pritchard et al. Nature Communications
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
- (2013) Paul F. Schellhammer et al. UROLOGY
- Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer
- (2012) Raquibul Hannan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- The genomic complexity of primary human prostate cancer
- (2011) Michael F. Berger et al. NATURE
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
- (2009) Ravi A Madan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Development of a Listeria monocytogenes based vaccine against prostate cancer
- (2008) Vafa Shahabi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now